Inovio Pharmaceuticals, Inc.
INO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001055726
No open-market purchases or sales by Inovio Pharmaceuticals, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $36.1M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Inovio Pharmaceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- +4 vs. Q1 2026
- Shares held
- 32.8M
- +4.75M (+16.9%) vs. Q1 2026
- Total value
- $36.1M
- −$12.7M (−26.0%) vs. Q1 2026
- New holders
- 22
- 27 more added
- Sold out
- 18
- 15 more reduced
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 101 | $36.1M |
| Q1 2026 | 99 | $54.6M |
| Q4 2025 | 101 | $57.5M |
| Q3 2025 | 99 | $48.4M |
| Q2 2025 | 103 | $20.7M |
| Q1 2025 | 108 | $22.2M |
| Q4 2024 | 105 | $24.4M |
| Q3 2024 | 98 | $49.5M |
| Q2 2024 | 96 | $65.1M |
| Q1 2024 | 89 | $56.4M |
| Q4 2023 | 116 | $25.7M |
| Q3 2023 | 127 | $21.6M |
| Q2 2023 | 135 | $32.1M |
| Q1 2023 | 177 | $99.8M |
| Q4 2022 | 186 | $198.5M |
| Q3 2022 | 183 | $200.0M |
| Q2 2022 | 185 | $196.2M |
| Q1 2022 | 201 | $330.4M |
| Q4 2021 | 209 | $428.9M |
| Q3 2021 | 213 | $554.9M |
| Q2 2021 | 211 | $683.1M |
| Q1 2021 | 219 | $693.7M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Inovio Pharmaceuticals, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Hantz Financial Services, Inc. | 8 | $0 | 0.00% | 00.0% | Unchanged |
| Persistent Asset Partners Ltd | 0 | $0 | 0.00% | −142,164−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −804,958−100.0% | Sold out |
| Diadema Partners LP | 0 | $0 | 0.00% | −562,665−100.0% | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −248,790−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −56,862−100.0% | Sold out |
| CIBC Bancorp USA Inc. | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| IMC-Chicago, LLC | 0 | $0 | 0.00% | −37,889−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −32,677−100.0% | Sold out |
| Nine Masts Capital Ltd | 0 | $0 | 0.00% | −26,317−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −24,491−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −14,651−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −13,187−100.0% | Sold out |
| Legacy Wealth Managment, LLC | 0 | $0 | 0.00% | −1,356−100.0% | Sold out |
| MAI Capital Management | 0 | $0 | 0.00% | −830−100.0% | Sold out |
| Rhumbline Advisers | 0 | $0 | 0.00% | −602−100.0% | Sold out |
| Clearstead Advisors, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Root Financial Partners, LLC | 0 | $0 | 0.00% | −208−100.0% | Sold out |
| HM Payson & Co | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Janus Henderson Group PLC | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |